{"nctId":"NCT02458287","briefTitle":"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia","startDateStruct":{"date":"2015-06","type":"ACTUAL"},"conditions":["Hyperlipidemia"],"count":299,"armGroups":[{"label":"Bococizumab 150mg","type":"EXPERIMENTAL","interventionNames":["Biological: Bococizumab 150mg"]},{"label":"Bococizumab 75mg","type":"EXPERIMENTAL","interventionNames":["Biological: Bococizumab 75mg"]},{"label":"Bococizumab 150mg placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Bococizumab 150mg placebo"]},{"label":"Bococizumab 75mg placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Bococizumab 75mg placebo"]}],"interventions":[{"name":"Bococizumab 150mg","otherNames":[]},{"name":"Bococizumab 75mg","otherNames":[]},{"name":"Bococizumab 150mg placebo","otherNames":[]},{"name":"Bococizumab 75mg placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Treated with a statin - Fasting LDL-C \\>=70mg/dL and triglycerides \\<=400mg/dL\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding females - Cardiovascular or cerebrovascular event or procedures during the past 90 days - Congestive heart failure NYHA class IV - Poorly controlled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"3.57"},{"groupId":"OG001","value":"-57.2","spread":"2.57"}]}]}]},{"type":"PRIMARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 0 (Day 1)","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 2","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 4","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 6","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 8","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 10","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 75 mg Dose Group and Combined Bococizumab 150 mg and 75 mg Dose Group at Week 0 (Day 1), 2, 4, 6, 8 and 10","description":"A successful injection based on PAT was an injection where the participant answered \"yes\" to all the three questions: \"Were you able to inject your medicine?\" \"Has the blue bar moved across the window?\" Was the medicine not flowing after needle withdrawn?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"96.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Injections That Met the Definition for Successful Assessment Using the Observer Assessment Tool (OAT) for Bococizumab 150 mg Dose, Bococizumab 75 mg Dose Group and Combined Bococizumab 150 mg and 75 mg Dose Group at Week 0 (Day 1), 4 and 8","description":"As per the OAT, a 'successful' injection was based on observer's response for the question - \"Was the administration successful?''. Observer's response being 'Yes' corresponded to a successful injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"99.0","spread":null},{"groupId":"OG002","value":"96.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 75 mg Dose Group and Matched Placebo","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"3.74"},{"groupId":"OG001","value":"-36.0","spread":"2.55"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"2.33"},{"groupId":"OG001","value":"-35.9","spread":"1.67"},{"groupId":"OG002","value":"4.7","spread":"2.45"},{"groupId":"OG003","value":"-22.0","spread":"1.66"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"3.44"},{"groupId":"OG001","value":"-53.4","spread":"2.48"},{"groupId":"OG002","value":"4.3","spread":"3.62"},{"groupId":"OG003","value":"-31.5","spread":"2.46"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Non- High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"3.12"},{"groupId":"OG001","value":"-52.1","spread":"2.24"},{"groupId":"OG002","value":"4.7","spread":"3.30"},{"groupId":"OG003","value":"-32.5","spread":"2.23"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the follow up visit (up to 18 weeks), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)","description":"Percentage of participants with at least 1 positive ADA titer or 1 positive nAb titer were reported. Participants with their ADA titer levels \\>=6.23 were considered as ADA positive and participants with their nAb titer level \\>=1.58 were considered as nAb positive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Bococizumab at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.68","spread":"6.169"},{"groupId":"OG001","value":"2.08","spread":"1.413"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) at Week 12","description":"PCSK9 is an enzyme encoded by the PCSK9 gene in humans on chromosome. It is the 9th member of the proprotein convertase family of proteins that activate other proteins.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"297.9","spread":"102.11"},{"groupId":"OG001","value":"2835.3","spread":"901.15"},{"groupId":"OG002","value":"341.8","spread":"102.91"},{"groupId":"OG003","value":"2370.9","spread":"1016.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Upper respiratory tract infection","Diarrhoea","Nasopharyngitis"]}}}